Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CEDAR: Chemoradiation with Enadenotucirev as a radiosensitiser in locally advanced colorectal cancer


This phase I study will test the combination of a novel oncolytic virus (Enadenotucirev) with radical chemoradiation, prior to surgery in patients with locally advanced rectal cancer who are deemed suitable for curative treatment. Research Question: Is the combination of Enadenotucirev (EnAd) radical radiotherapy safe and tolerable in locally advanced rectal cancer? Primary Objective: To determine the safety, toxicity profile and MTD (or phase II dose if MTD not reached) of Enadenotucirev administered concomitantly with chemoradiation (CRT) for locally advanced rectal cancer. Primary endpoint: The highest number schedule that has no more than 30% grade 3 and 4 toxicity. DLT will be defined as per NCI CTCAE v4.03 and include Grade ≥4 Haem toxicity, Grade ≥4 GI toxicity within 2 weeks of starting radiotherapy, any grade ≥4 considered related to study treatment, including pneumonitis, or other cytokine release syndrome.